Context: Ustekinumab is a human IgG1 monoclonal antibody that targets interleukin (IL)-12 and IL-23, which may be useful in the treatment of autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn's disease. Hypophysitis is an immune-derived inflammatory condition of the pituitary gland that may lead to pituitary dysfunction. With the increasing use of immunotherapy, it is possible that this and other new immune-related adverse events (IRAEs) arise, although the mechanisms involved are still incompletely defined.
Hypophysitis is an immune-derived inflammatory condition of the pituitary gland that may lead to pituitary dysfunction. With the increasing use of immunotherapy, it is possible that this and other new immune-related adverse events (IRAEs) will continue to arise.
We here describe the case of a patient who developed hypophysitis following ustekinumab treatment for psoriasis. We suggest potential mechanisms involved in its pathogenesis.
Case RepoRt
A 35-year-old male, with a previous history of severe plaquepsoriasis who had started treatment with ustekinumab 4 months before, complained of progressive and persistent headache, which was refractory to non-steroidal anti-inflammatory drugs. Brain magnetic resonance imaging (MRI) was unremarkable. One year later, a new MRI was performed due to headache persistence, which revealed a homogenous and diffuse pituitary enlargement of up to 1.1 cm, which extended to the suprasellar region and contacted the optic quiasm, blurring of the pituitary stalk, absence of clear differentiation between the anterior and posterior lobes, and no signs of hemorrhage or adenomas (Figure 1) . Visual fields were normal. The patient acknowledged absence of signs or symptoms suggestive of pituitary dysfunction, except for mild libido decrease and erection difficulties. Physical examination revealed multiple psoriatic plaques, with no other remarkable features. Laboratory work-up was consistent with hypogonadotropic hypogonadism, central hypothyroidism, central hypoadrenalism, and GH deficiency, but normality in the rest of the biochemical parameters evaluated (ions, proteins, lipid, renal, and hepatic profiles). Cerebrospinal fluid and work-up of infiltrative and infectious diseases, including sarcoidosis and tuberculosis, were negative. Follow-up MRI performed 6 months later revealed an increase in the pituitary enlargement to up to 1.7 cm. Because etiology of the mass was still unclear, the patient underwent transsphenoidal surgery of the sellar mass, with the purposes of both debulking and obtaining samples for biopsy.
Pathological findings revealed and intense fibrosis and a chronic inflammatory infiltrate of the pituitary gland with a high proportion of lymphocytes and some plasmatic cells, but no evidence of adenoma, granuloma, or acid fast bacilli. Immunohistochemistry pointed to a combined T-cell (CD3+, CD4+, CD8+) and B-cell (CD19+, CD20+) phenotype. Additional immune analysis showed positivity for FOXP3, PD1, and IL-17, and negativity for IgG4 and S-100 protein (Figure 2) .
Ustekinumab was withdrawn, with subsequent improvement of headaches. Laboratory work-up after surgery revealed persistent panhypopituitarism, so hormonal replacement therapy was maintained. No other autoimmune disorders were evidenced in the clinical or analytical follow-up evaluation.
DisCUssioN
The use of ustekinumab for the treatment of psoriasis has progressively increased in recent years. Common side-effects include mild gastro-intestinal disturbance, dizziness, depression, cold symptoms, and artro-myalgias. More severe effects include allergic hyper-sensibility and opportunistic infections such as tuberculosis. However, although there is a potential risk of developing other IRAEs, this has been less explored (1) .
Recently developed immunotherapeutic agents, which act as immune checkpoint inhibitors by releasing constraints on immune cells to promote antitumor activity, have generated promising results; specifically, the IgG1 monoclonal antibody Ipilimumab, which binds and inhibits cytotoxic T-lymphocyte antigen-4, or the IgG4 monoclonal antibodies Nivolumab and Pembrolizumab, which bind PD1. However, the immunemediated antitumor effect frequently entails the development of other endocrine IRAEs, including hypophysitis, hypothyroidism, and adrenal insufficiency, especially in the case of Ipilimumab (3, 4) . The reasons for these findings are still not fully understood but may concern modifications in the self-reactive effector T-cell repertoire and a further release of pituitary self-antigens, once pituitary inflammation and damage initiates, leading to the generation of more pituitary-reactive T-cells (4) .
In this case report, hypophysitis possibly developed after treatment with ustekinumab, another monoclonal antibody. IgG4-mediated hypophysitis was reasonably ruled, given the negative pituitary IgG4 reactivity by immunohistochemistry, the absence of characteristic histopathologic findings, and the absence of any other clinical sign or symptom of IgG4-related disease at another site (5) . Also, other causes of hypophysitis, such as histiocytosis, sarcoidosis, or tuberculosis, were reasonably ruled out with further clinical and laboratory work-up. It is true that a potential association between psoriasis and hypophysitis has been vaguely suggested (6) , and lymphocytic and granulomatous hypophysitis have been anecdotally described in the setting of a past medical history of psoriasis, but with no clearly documented relationship (7, 8) . However, in our patient, the absence of a correlation between the clinical course of both entities, the stability of skin plaques since the introduction of ustekinumab, the absence of any other autoimmune condition which could further be related to the potential development of hypophysitis, and the immunohistochemical pattern observed may reasonably exclude the role of psoriasis in the development of this patient's hypophysitis.
We suggest for the first time a case of a possible ustekinumabinduced hypophysitis. In addition, apart from the biochemical work-up and radiological images, we provide novel immunehistopathological findings. We observed a predominance of T-cells (CD3+, CD4+), which is characteristic of lymphocytic hypophysitis (9) , and no granulomas. Specifically, the positive phenotypic expression for FOXP3 and PD1 suggests the presence of T-regulatory cells (Tregs). Although finding Tregs in hypophysitis may seem paradoxical, it could be hypothesized that treatment with ustekinumab could originate aberrant Tregs and entail an imbalance in the lymphocytic profile (9) .
On the other hand, IL-17 expression, which is characteristic of Th17 cells, was present in both infiltrating lymphocytes and also in pituitary cells in a similar grade as in normal pituitary tissue. Finding IL-17 expression in a similar grade in both infiltrating lymphocytes and normal pituitary cells could be due to the development of hypophysitis itself. In fact, T lymphocytes undergo activation in the pituitary gland and produce increased levels of ILs, including IL-17, perpetuating the alteration. Normal pituitary cells do not usually express IL-17, in contrast to infiltrating lymphocytes and pituitary cells in the setting of hypophysitis, which do so. Moreover, the plasticity of Th cells and the existence of at least two subsets of Th17 lymphocytes, pathogenic or proinflammatory, and non-pathogenic subsets, has been recently described (10) and can be identified by multiparametric flow cytometry, with analysis of the expression of the chemokine receptor CXCR3 (CD183), the P-glycoprotein 1 or multidrug resistance protein 1 (MDR1 or CD243), the differentiation molecule CD161, and the presence of IL-17 and IFN-γ. Moreover, IL-23 has been described to have a critical role on the differentiation of pathogenic Th17 cells (11) . By contrast, non-pathogenic Th17 cells could participate in the regulation of the inflammatory phenomenon (12, 13) . In this regard, it has been suggested that non-pathogenic Th17 cells can differentiate into Treg lymphocytes, contributing to the downregulation of autoimmunity and chronic inflammatory conditions (14) . In view of these findings, we can suggest that if IL-23 levels are altered due to ustekinumab, the balance between Th17 pathogenic and non-pathogenic cells may also be altered, resulting, in an aberrant lymphocytic infiltration, meaning that hypophysitis may consequently develop and perpetuate. In this way, ustekinumab-induced hypophysitis could represent various the lymphocytic-mediated model.
In conclusion, we suggest a novel IRAE of ustekinumab, which may be mediated by the complex interaction between cytokines, Treg and different Th subsets, and we provide full radiological and immunopathological iconography. The presence of a previous history of psoriasis, which is an autoimmune disease, may disguise a full comprehension of the mechanisms involved, given the potential combination of concomitant immune alterations. Further tissue and peripheral blood evaluation, also in the setting of other immune checkpoint inhibitors, may help understand the broad spectrum of hypophysitis, and evaluate the possible different T-cell profile observed.
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